Compound Maduramicin Ammonium Premix (Maduramicin Ammonium and Nicarbazin Premix) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a dual-active coccidiostat blending system rather than a single purified molecular entity. The premix is supplied as a free-flowing microgranular material for further processing into oral solid and liquid dosage forms; the term veterinary grade API indicates that the material is intended for pharmaceutical or medicated-feed manufacture under appropriate good manufacturing practice. Maduramicin ammonium is a polyether ionophore antibiotic, and nicarbazin is a molecular complex of 4,4′-dinitrocarbanilide and 2-hydroxy-4,6-dimethylpyrimidine. The product has no harmonised ISO or pharmacopoeial model number; procurement must therefore be governed by the approved marketing authorisation, the certificate of analysis, and the manufacturer’s grade designation. Where a registered oral premix label states 10 g/kg maduramicin ammonium and 125 g/kg nicarbazin equivalents, the mixture is intended only for oral anticoccidial application in indicated poultry species under veterinary supervision. The same article is not approved as a generic growth promoter or as a broad-spectrum antibacterial.

Because the two active substances have markedly different solubility and stability behaviour, the premix cannot be considered an inert dry blend. Nicarbazin is practically insoluble in water, and maduramicin ammonium is poorly water soluble; these constraints define the practical formulation windows for solutions, suspensions, tablets, capsules, and injectables. A calcium carbonate carrier may raise the pH of the wetted premix to 8.0–9.0, which improves nicarbazin stability but increases hygroscopicity at relative humidity above 60%. Rice hull and corncob carriers provide lower dust but can segregate during high-speed capsule filling because of elongated or irregular particle shape. Synthetic silica is used where low moisture and free flow are critical, but its dust potential requires local exhaust ventilation and respiratory protection during manual weighing.

Typical incoming release testing for the material includes assay of each active separately, loss on drying, residue on ignition, heavy metals, particle size distribution, and microbiological quality. A release specification of 90.0–110.0% of declared potency for each active is common in commercial dossiers, but the approved specification in any jurisdiction may differ. Limits for lead, arsenic, cadmium, and mercury are established as part of the manufacturer’s risk assessment under ICH Q3D and VICH GL18 or equivalent regional standards. For medicated-feed premixes, sampling and sample preparation are guided by ISO 6497:2002 and ISO 6498:2012, although finished-product release in the veterinary pharmaceutical sector more commonly follows pharmacopoeial general chapters.

What Limits the Use of This Combined Premix in Injectable and True-Solution Dosage Forms?

Injectable preparations are not the default use of a maduramicin–nicarbazin premix. Both active substances are practically insoluble in water, and a simple aqueous injection would produce a suspension with unacceptable syringeability and dose uniformity. To produce a stable injectable suspension, wet milling through a colloid mill or high-pressure homogenizer is required until the median particle size is below 10 µm. Even then, the tissue residue profile is more complex than the oral profile; residue depletion studies must include parent maduramicin in liver or fat and DNC in eggs or muscle as applicable. Published data for this specific combination as an injectable is limited, and no compendial injectable monograph is routinely applied. Solutions should be considered feasible only in non-aqueous solvent systems or co-solvent vehicles that have been validated for target-species safety, tissue tolerability, and withdrawal time. Acidic vehicles below pH 4.0 are undesirable because nicarbazin can dissociate into DNC and HDP, and DNC has very low solubility in aqueous buffers at pH 5.0. Oral solutions labelled as “solutions” often require a suspending agent and a thixotropic vehicle; the label must state the actual physical form if a true solution cannot be achieved.

Assay Selectivity, Carrier Interference, and Release Limits for the Mixed Premix

Quantification of the two active substances is not performed as a single total coccidiostat assay. Nicarbazin is measured as DNC by reversed-phase HPLC with ultraviolet detection at 340 nm to 365 nm, while maduramicin ammonium, which lacks a strong UV chromophore, is determined by liquid chromatography with tandem mass spectrometric detection or evaporative light-scattering detection. A validated method must separate DNC from 2-hydroxy-4,6-dimethylpyrimidine and from carrier-derived matrix peaks. Table 1 shows an illustrative release specification for a mixed premix; values are not substitutes for the registered limits in any market.

Storage stability of the dual premix is influenced by light, moisture, and alkaline hydrolysis. Master batch records for similar coccidiostat premixes commonly specify storage below 30 °C and protection from light in amber poly-lined bags. During fluid-bed granulation, inlet air temperature is typically limited to 45–55 °C to avoid thermal degradation of the ionophore; if steam conditioning is required for feed pelleting, the conditioned meal should not exceed 70 °C unless stability data demonstrate otherwise. Residual moisture above 8.0% has been linked in production-scale batches to punch face filming on rotary tablet presses and to bridge formation in capsule hoppers. Where the manufacturing site operates at relative humidity above 60%, pre-drying of the carrier or controlled humidity suites is recommended before direct compression.

Extractables from polyvinyl chloride packaging have not been fully characterised for this dual premix. Primary packaging should be low-density polyethylene or laminated aluminium with a heat-sealed closure; light-resistant containers are specified because the nicarbazin component is photolabile. The carrier can settle during transport, so on receipt the material should be remixed or tumbled before sampling from the top third of the container. Sampling procedures must be documented to ensure that assays reflect the entire container and not a settled layer.

When Dry Granulation Is Replaced by Direct Compression, the Carrier Grade Determines Content Uniformity

In tablet and capsule manufacture, the premix is typically screened through a 0.600 mm sieve and incorporated into a lactose monohydrate/microcrystalline cellulose matrix. Direct compression is permissible only when the premix fraction of the final tablet weight is large enough to reduce segregation risk. In practice, batches with premix loading below 20% of final tablet weight have shown segregation of the low-density nicarbazin component during bin discharge and tablet press feed. High-shear granulation or roller compaction is therefore preferred for low-dose oral tablets. The process must be validated against Ph. Eur. 2.9.40 or USP 905 for uniformity of dosage units; production data using pilot twin-shell blenders indicate that a blend time of 15–25 min at 60–80% of vessel fill volume frequently achieves a potency relative standard deviation below 5.0%, but this is matrix-dependent. Tablet hardness, friability, and disintegration time should be recorded according to Ph. Eur. 2.9.8 and USP 701 because the hydrophobic actives can prolong disintegration if not adequately dispersed by the disintegrant.

Granulation endpoint is commonly determined by loss on drying below 2.0% after drying and by particle size distribution with a target fraction above 0.150 mm and below 0.850 mm. Oversized granules returning through a mill require low mill speed to avoid heat generation above 40 °C. The addition sequence in the granulator is also controlled: nicarbazin-containing premix is preferably dispersed into the dry binder before the liquid binder is introduced, because direct spraying onto the premix fraction can create low-density agglomerates with poor erosion resistance.

Anticoccidial Spectrum, Dose Positioning, and Withdrawal-Time Differences Compared with Monotherapy Products

The combined product differs from monotherapy not by simple additive concentration but by the overlap of two distinct coccidiocidal mechanisms. Maduramicin ammonium acts as an ionophore and disrupts sodium, potassium, and calcium gradients across the cell membranes of Eimeria sporozoites and merozoites. Nicarbazin, through the DNC component, suppresses sexual and asexual stages of Eimeria and has a different intra-intestinal distribution. A registered maduramicin monotherapy feed may be used at 5–7.5 mg/kg complete feed; nicarbazin monotherapy is used at approximately 125 mg/kg complete feed. The compound premix label is species-specific and must not be extrapolated from those monotherapy values. In jurisdictions where the combination is authorised, the label may require a withdrawal period longer than that of maduramicin alone because of the nicarbazin residue component.

Compared with narasin–nicarbazin premixes, the present product uses maduramicin ammonium at a lower mass-based dose than narasin and therefore reduces the absolute ionophore mass per tonne of finished feed where such a substitution is permitted. This does not reduce the ionophore class hazard to horses, because equine toxicity is not solely dependent on feed concentration. The nicarbazin fraction creates the same DNC egg-residue concern as other nicarbazin-containing products. The analytical methods also differ; methods validated for narasin are not directly applicable to maduramicin because of different extraction recoveries and ion chromatographic conditions. Any published comparative trial that used narasin–nicarbazin cannot be transferred directly to this combination without explicit bridging data.

Resistance-management claims must be limited to approved labels and supported by challenge models. The dual mechanism can reduce the probability of single-agent resistance in controlled coccidial isolates, but published data for this specific combination is limited relative to the more extensively studied narasin–nicarbazin pair. The product is not a broad-spectrum anticoccidial improvisation; its dose, duration, target species, and withdrawal period are safety-critical because the maduramicin component has a narrow therapeutic index in some avian species and the nicarbazin component has well-documented residue implications. In absence of local approval, formulation into tablets, capsules, or feed premixes must be treated as an investigational use requiring target-animal safety and residue depletion studies.

Dedicated Facility Segregation Is Not Optional for Ionophore-Containing Premixes

Manufacturing of a maduramicin-containing premix requires facility segregation and validated cleaning, because carryover of polyether ionophores into equine or turkey feed can be lethal. Dedicated scoops, bins, and blend tools are used in facilities handling multiple medicated premixes. After a batch, cleaning validation should include swab or rinse sampling for maduramicin and nicarbazin markers; acceptance limits are based on the toxicity of the next product and the cleaning factor. Medicated-feed mills should verify mixer homogeneity according to ISO 6497:2002 or regional feed-sampling protocols. Feed batch records must document the sequence of addition, flush material handling, and the results of active recovery at multiple points. In feed processing, addition of coccidiostat premix before high-temperature pelleting is only acceptable when the feed and the active have documented thermal stability; otherwise, post-pelleting liquid spray or conditioning at reduced temperature is required.

In oral powders and granules, the active premix is usually diluted with a non-medicated carrier at ratios from 1:10 to 1:1000. Geometric dilution is required because direct addition of the high-potency premix to a ribbon blender can produce localised zones of high nicarbazin concentration. A content uniformity coefficient of variation below 5.0% in the final mixture is regarded as a practical production target; however, the regulatory acceptance criterion is set by the dosage form and the applicable pharmacopoeia. The material should not be mixed with strongly acidic excipients or oxidising agents, as acidic conditions may dissociate nicarbazin and oxidising agents may degrade the polyether ionophore. Finished oral suspensions require preservative efficacy testing according to Ph. Eur. 5.1.3 or USP 51 if water is present in the vehicle.